Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Search
Speak up
We are committed to conducting business with integrity and in compliance with applicable laws, regulations, company policies and procedures.
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia
Boehringer Ingelheim is driving localization capacities with robust partnerships in alignment with Vision 2030
Global Code of Conduct
Boehringer Ingelheim´s Global Code of Conduct
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Taking cancer on with smart combinations
Boehringer Ingelheim digs deep into the science and taking a precision approach to develop smart combinations to bring the greatest benefit to patients.
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
preventive care cat veterinarian
What can we all, cat owners or veterinarians, do to promote cat health? Click to find out!
Boehringer Ingelheim collaborates with local universities in Nairobi, Kenya to introduce
Boehringer Ingelheim collaborates with local universities in Nairobi, Kenya to introduce development program for young professionals
COVID-19: Research Update
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
First hospital uae and gcc receive international award stroke management
Ibrahim Bin Hamad Obaidullah Hospital Receives the Diamond Award from the World Stroke Organization
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Cardiometabolic Research
Read about our patient-centric approach to cardiometabolic disease research.
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
10 tips cat friendly veterinary clinics
Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
COVID-19 Global Access Commitment with Gates Foundation
Boehringer Ingelheim commits to provide global access to COVID-19 therapeutics by signing a communiqué with the Bill & Melinda Gates Foundation.
Boehringer Ingelheim announces Reach Africa Access Healthcare programs outcomes
Boehringer Ingelheim, announces “In Reach Africa” Access to Healthcare programs outcomes
Teaching kids about pet-care
Teaching kids about pet care
Fighting Negative KRAS Feedback
Boehringer Ingelheim scientists are directly targeting KRAS, blocking feedback and ultimately getting ahead of resistance by investigating pan-KRAS approaches. Article from Marco Hofmann